Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …

Background Numerous clinical trials and observational studies have investigated various
pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19) …

IL-6 is usually described as a pleiotropic cytokine produced in response to tissue injury or
infection. As a pro-inflammatory cytokine, IL-6 activates innate and adaptative immune …

Background There is accumulating evidence for an overly activated immune response in
severe COVID-19, with several studies exploring the therapeutic role of immunomodulation …

Introducción: La pandemia por SARS-Cov-2 ha tenido un impacto negativo en múltiples
aspectos de la vida humana, tanto en lo físico, psicológico, económico, social y cultural. Las …

Background The prevalence of bacterial infection in patients with COVID-19 is low, however,
empiric antibiotic use is high. Risk stratification may be needed to minimize unnecessary …

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases
or treatment of malignancies; it may also appear during the progression of COVID-19. CSS …